Media Releases

2022

12/05/2022

Proteomics International awarded $400,000 to support manufacturing capability in Australia

12/04/2022

New Clinical Advisory Board for PromarkerD global rollout

24/03/2022

PromarkerD patent granted in India

22/02/2022

PromarkerD completes ‘pre-assessment’ for Medicare rebate

07/02/2022

Novel biomarkers identified for Asthma and COPD

04/02/2022

Unique panel of biomarkers identified for oesophageal cancer

31/01/2022

January Newsletter 2022

2021

16/12/2021

Proteomics secures major pharmacokinetic testing contract

24/11/2021

FDA advises regulatory pathway for PromarkerD in US

23/11/2021

PromarkerD distribution network expands to Britain

16/11/2021

New Directors appointed to Company Board

05/11/2021

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

03/11/2021

Proteomics International awarded $100,000 manufacturing funding

12/08/2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

11/08/2021

Diabetes treatment lowers PromarkerD risk score: Results presented at Australasian Diabetes Congress

1
2
3
4
5
6
7
8
9